Stereotaxis, Inc. (STXS)
| Market Cap | 105.21M -62.2% |
| Revenue (ttm) | 30.07M -5.5% |
| Net Income | -23.59M |
| EPS | -0.24 |
| Shares Out | 100.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 641,345 |
| Open | 1.030 |
| Previous Close | 1.050 |
| Day's Range | 1.030 - 1.055 |
| 52-Week Range | 1.020 - 3.204 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+185.71%) |
| Earnings Date | Aug 11, 2026 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]
Financial Performance
In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price target is $3.0, which is an increase of 185.71% from the latest price.
News
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026
New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept.
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Elec...
Stereotaxis price target lowered to $3 from $4 at Citizens
Citizens analyst Daniel Stauder lowered the firm’s price target on Stereotaxis (STXS) to $3 from $4 and keeps an Outperform rating on the shares. Stereotaxis reported a slight Q2 revenue…
Stereotaxis Slides: Investor presentation
Stereotaxis has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Stereotaxis price target lowered to $3 from $4 at Lake Street
Lake Street lowered the firm’s price target on Stereotaxis (STXS) to $3 from $4 and keeps a Buy rating on the shares after resetting its model to reflect the company’s…
Stereotaxis price target lowered to $3 from $5 at TD Cowen
TD Cowen lowered the firm’s price target on Stereotaxis (STXS) to $3 from $5 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Stereotaxis Earnings Call Transcript: Q2 2026
Q2 2026 saw accelerating adoption of new robotic and digital products, with recurring revenue up 270% sequentially and robust physician feedback. Supply constraints limit catheter revenue growth, but guidance anticipates strong recurring and system revenue in the second half, with cash flow profitability targeted for early 2027.
Stereotaxis Earnings release: Q2 2026
Stereotaxis released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Stereotaxis Quarterly report: Q2 2026
Stereotaxis has published its Q2 2026 quarterly earnings report on August 11, 2026.
Stereotaxis reports Q2 EPS (5c), consensus (5c)
Reports Q2 revenue $7.67M, consensus $8.35M. “Stereotaxis (STXS) has reached an important commercial inflection point. Following years of product development and regulatory milestones, the Company’s e...
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business u...
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it ...
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac a...
Stereotaxis files to sell 108.87M shares of common stock for holders
17:27 EDT Stereotaxis (STXS) files to sell 108.87M shares of common stock for holders
Stereotaxis files to sell 19.45M shares of common stock for holders
17:23 EDT Stereotaxis (STXS) files to sell 19.45M shares of common stock for holders
Stereotaxis Registration statement: Registration filing
Stereotaxis filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.
Stereotaxis Registration statement: Registration filing
Stereotaxis filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.
Stereotaxis Completes Acquisition of Robocath
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announ...
Stereotaxis management to meet with BTIG
Meeting to be held in New York on July 7-10 hosted by BTIG.
Stereotaxis Slides: Investor presentation
Stereotaxis has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Stereotaxis price target lowered to $3.50 from $4 at Piper Sandler
Piper Sandler lowered the firm’s price target on Stereotaxis (STXS) to $3.50 from $4 and keeps an Overweight rating on the shares following quarterly results. Stereotaxis noted some headwinds to…
Stereotaxis Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue decline due to transition from legacy products, but regulatory approvals and new product launches signal a foundational shift. Strong demand for new catheters and digital systems, plus the Robocath acquisition, support double-digit revenue growth guidance for 2026.
Stereotaxis Earnings release: Q1 2026
Stereotaxis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Stereotaxis Quarterly report: Q1 2026
Stereotaxis has published its Q1 2026 quarterly earnings report on May 12, 2026.
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates...